Evidence map›Paper›PMID 26896963›Full record

Trial reportCancer chemotherapy and pharmacology2016

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.

Yoshihiro Tanaka, Kazuhiro Yoshida, Atsuko Yamada, Toshiyuki Tanahashi, Naoki Okumura, Nobuhisa Matsuhashi, Kazuya Yamaguchi, Tatsuhiko Miyazaki

Erratum issuedAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Efficacy and safety of FLOT regimenResearch in pharmaceutical sciences · 2022
    Article
  8. Serum diamine oxidase activity derived from response to chemotherapy affects adverse events and serum amino acid levels.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Recent advancements in esophageal cancer treatment in Japan.Annals of gastroenterological surgery · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yoshihiro TanakaDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. yoshihirotana11@hotmail.com.
Kazuhiro YoshidaDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Atsuko YamadaDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Toshiyuki TanahashiDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Naoki OkumuraDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Nobuhisa MatsuhashiDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Kazuya YamaguchiDepartment of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Tatsuhiko MiyazakiDepartment of Pathology, Gifu University Hospital, Gifu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of esophageal cancer patients is still unsatisfactory. Although a docetaxel, cisplatin, and 5-Fu (DCF) regimen has been reported, it is often difficult to accomplish because of severe toxicity. Therefore, we developed a new biweekly DCF (Bi-DCF) regimen and previously reported the recommended dose in a phase I dose-escalation study. We then performed a phase II study of Bi-DCF for advanced esophageal squamous cell carcinoma (SCC). Patients with clinical stage II/III were eligible. Patients received 2 courses of chemotherapy: docetaxel 35 mg/m(2) with cisplatin 40 mg/m(2) on days 1 and 15 and 400 mg/m(2) 5-fluorouracil on days 1-5 and 15-19 every 4 weeks. After completion of the chemotherapy, patients received esophagectomy. The primary endpoint was the completion rate of protocol treatment. Thirty-two patients were enrolled. The completion rate of protocol treatment (completion of two courses of preoperative chemotherapy and R0 surgery) was 100 %. During chemotherapy, the most common grade 3 or 4 toxicities were neutropenia (31.3 %). No treatment-related death was observed, and the incidence of operative morbidity was tolerable. The overall response rate after the chemotherapy was 90.3 %. This Bi-DCF regimen was well tolerated and highly active. This trial was registered with the University Hospital Medical Information Network (No. UMIN 000014625).

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCisplatinDocetaxelDrug Administration ScheduleEsophageal NeoplasmsFemaleFluorouracilHumansMaleMiddle AgedNeoplasm StagingTaxoidsCisplatinDocetaxelFluorouracilTaxoids5-fluorouracilChemotherapyCisplatinDocetaxelEsophageal carcinoma

Identifiers

PMID26896963
PMCPMC4882360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.